Abstract:The interim analysis of our prospective trial, which compared irradiation to pre-chemotherapy or post-chemotherapy tumour extent while application of involved field radiotherapy (IFRT) for limited-stage small cell lung cancer (SCLC), showed that reduced field did not result in increased local/regional out-field recurrence. This report presents the final results of the clinical study with radiation dosimetric and pathologic analysis as interpretations. Chemotherapy consisted of 4 to 6 cycles of etoposide and cisplatin (EP). After 2 cycles of EP, patients were randomly assigned to receive thoracic radiotherapy (TRT) to either the post- or pre-chemotherapy tumour extent as study arm or control. TRT was administered concurrently with cycle 3 chemotherapy. IFRT was applied for both arms. The lymph node regions (groups 1 to 10) were contoured in treatment planning system. The intentional or incidental radiation doses to each lymph node regions were recorded. Patients with stage T1-2N0-1M0 SCLC received radical lobectomy. The minimal distances between microscopic nidus and the edge of gross tumor were measured. The clinical target volume of the primary tumor (CTV-T) was defined as the margins covering 95% of microscopic disease extension. Between June, 2002 and January, 2017, 159 and 150 patients were randomly assigned to study arm or control. The 1-, 3-, and 5-year local/regional progression free probability were 79.4%, 60.1% and 60.1% respectively in the study arm versus 79.8%, 64.5%, and 57.3% in the control (p=0.73). The median overall survival (OS) time was 22.1 months in the study arm (95% CI, 18.2-26.0) and 26.9 months (95% CI, 23.5-30.3) in the control, the 1-, 3-, 5-, and 7-year OS rates were 81.1%, 31.6%, 23.9% and 22.2% respectively in the study arm versus 85.3%, 36.6%, 26.1% and 20.0% in the control arm (p=0.51). A total of 1680 lymph node regions in 105 patients were contoured. The lymph node regions that received incidental radiation doses over 30Gy were: 7, 3P, 4L, 6, 4R, 5 and 2L. Eight patients were enrolled in the pathologic evaluation of CTV-T. The median range of CTV-T in patients received or did not receive neoadjuvant chemotherapy were 0.4mm and 1.7mm respectively, a margin of 1.4mm and 10.2mm could cover 95% of microscopic nidus extension respectively (p=0.00). Irradiating post-chemotherapy tumour extent and applicant of IFRT didn't increase local/regional failure, and the OS difference wasn't statistically significant between the two arms. TRT could be limited to post-chemotherapy tumour extent, while IFRT could be routinely applied for limited-stage SCLC patients.

Feasibility of Omitting Clinical Target Volume for Limited-Disease Small Cell Lung Cancer Treated with Chemotherapy and Intensity-Modulated Radiotherapy

Retrospective analysis of omitting clinical target volume for patients with stage Ⅲ non-small cell lung cancer treated with intensity-modulated radiotherapy

Feasibility of Omitting the Clinical Target Volume under PET-CT Guidance in Unresectable Stage III Non-Small-cell Lung Cancer: A Phase II Clinical Trial

Efficacy of the Smaller Target Volume for Stage III Non-Small Cell Lung Cancer Treated with Intensity-Modulated Radiotherapy.

Omitting Elective Nodal Irradiation and Irradiating Postinduction Versus Preinduction Chemotherapy Tumor Extent for Limited‐stage Small Cell Lung Cancer

Omitting elective nodal irradiation and irradiating postinduction versus preinduction chemotherapy tumor extent for limited-stage small cell lung cancer: interim analysis of a prospective randomized noninferiority trial.

Is it necessary to prescribe the same dose to subclinical lesions as gross tumor volume in non-small-cell lung cancer? —a failure pattern analysis

A prospective randomized study of the radiotherapy volume for limited-stage small cell lung cancer: a preliminary report]

P3.14-004 Pathological Study on the Clinical Target Volume (CTV) in Limited-Stage SCLC for CT-Simulation Based Thoracic Radiotherapy Planning

The Prognosis and Feasibility of Extensive Clinical Target Volume in Postoperative Radiotherapy for Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial

Final report of a prospective randomized study on thoracic radiotherapy target volumes for limited-stage small cell lung cancer

OA13.06 Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volumes with Radiation Dosimetric and Pathologic Analyses

Is clinical target volume necessary for locally advanced non-small cell lung cancer treated with 4D-CT intensity-modulated radiation therapy

Clinical Outcomes and Prognostic Factors in Limited-Stage Small Cell Lung Cancer Patients Treated with Intensive Modified Radiation Therapy

Preliminary Results about Application of Intensity-Modulated Radiotherapy to Reduce Prophylactic Radiation Dose in Limited-Stage Small Cell Lung Cancer

Quantitative Analysis of Tumor Shrinkage Due to Chemotherapy and Its Implication for Radiation Treatment Planning in Limited-Stage Small-Cell Lung Cancer

Can Radiation Therapy Be Omitted in Patients with Early-Stage NK/T-Cell Lymphoma Who Achieved Complete Response to Chemotherapy? A Multicenter Analysis

The Therapeutic Value of Volumetric-Modulated Arc Therapy In Advanced Non-Small Cell Lung Cancer Primary Tumors: A Multicenter Retrospective Analysis Based On Propensity Score Matching And Comparison With Intensity-Modulated Radiotherapy

Final Report of a Prospective Randomized Study on Thoracic Radiotherapy Target Volume for Limited-Stage Small Cell Lung Cancer with Radiation Dosimetric Analyses

Involved-field Radiotherapy for Patients with Limited Small Cell Lung Cancer: Patterns of Local-Regional Failure and Feasibility

Feasibility and Efficacy of Helical Intensity-Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer in Comparison with Conventionally Fractionated 3D-CRT.